Tango Therapeutics Upsized Public Offering
Analysis based on 8 articles · First reported Jun 08, 2026 · Last updated Jun 10, 2026
The public offering by Tango Therapeutics is expected to raise $600 million, providing significant capital for its operations and drug development, which could positively impact its stock price and future prospects. The involvement of major financial institutions like JPMorgan Chase, Leerink Partners, Cantor Fitzgerald, and Stifel as bookrunning managers indicates market confidence in the offering.
Tango Therapeutics, a clinical-stage biotechnology company, announced and subsequently priced an upsized underwritten public offering of its common stock and pre-funded warrants. Initially proposed at $500 million, the offering was priced to generate approximately $600 million in gross proceeds. The offering includes 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 1,833,395 shares at $29.999 per warrant. Tango Therapeutics will sell all shares and warrants, with the closing expected around June 11, 2026. The company also granted underwriters a 30-day option to purchase additional shares. JPMorgan Chase, Leerink Partners, Cantor Fitzgerald, and Stifel are serving as joint bookrunning managers for the offering.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard